PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Active compounds
Mechanism of action
Clinical evidence
The association between marine omega-3 supplementation and reduced risk of CVD remains controversial, with inconsistent results across various trials [PMID:31567003, PMID:31298156]. Some evidence indicates benefits for incident heart failure and all-cause mortality, but secondary prevention trials have not confirmed mortality benefits in survivors of myocardial infarction [PMID:22565141].
A randomized clinical trial investigated the effect of long-term supplementation (1 g/d fish oil) on the risk of depression and mood scores in adults [PMID:34932079].
Meta-analysis of RCTs indicates that the overall effects of omega-3 fatty acids on BPD symptoms remain unclear [PMID:34004088].
Randomized controlled trials have not consistently shown a benefit of fish oil for the maintenance of remission in Crohn's disease [PMID:33518163].
Safety & adverse effects
Pregnancy & lactation
Evidence summary
PubMed sources
- 1.PMID: 25149823 (2015) — Marine omega-3 fatty acids and inflammatory processes: Effects, mechanisms and clinical relevance. · Biochimica et biophysica acta
- 2.PMID: 31567003 (2019) — Marine Omega-3 Supplementation and Cardiovascular Disease: An Updated Meta-Analysis of 13 Randomized Controlled Trials Involving 127 477 Participants. · Journal of the American Heart Association
- 3.PMID: 34932079 (2021) — Effect of Long-term Supplementation With Marine Omega-3 Fatty Acids vs Placebo on Risk of Depression or Clinically Relevant Depressive Symptoms and on Change in Mood Scores: A Randomized Clinical Trial. · JAMA
- 4.PMID: 30542006 (2019) — Prevention of Fish Oil Oxidation. · Journal of oleo science
- 5.PMID: 33518163